Table 4.
Incidence of adverse events.
| AML5 (n = 89) |
AML5 + CC16 (n = 89) |
p-value | |
|---|---|---|---|
| General disorders | 1 (1.12) | 3 (3.37) | 0.6207 |
| Chest discomfort | 0 (0.00) | 2 (2.25) | 0.4972 |
| Chest pain | 0 (0.00) | 1 (1.12) | 1.0000 |
| Edema | 1 (1.12) | 0 (0.00) | 1.0000 |
| Nervous system disorders | 2 (2.25) | 2 (2.25) | 1.0000 |
| Head discomfort | 0 (0.00) | 1 (1.12) | 1.0000 |
| Headache | 0 (0.00) | 1 (1.12) | 1.0000 |
| Dizziness | 2 (2.25) | 0 (0.00) | 0.4972 |
| Gastrointestinal disorders | 0 (0.00) | 1 (1.12) | 1.0000 |
| Pancreatitis | 0 (0.00) | 1 (1.12) | 1.0000 |
| Infections and infestations | 1 (1.12) | 1 (1.12) | 1.0000 |
| Acute sinusitis | 0 (0.00) | 1 (1.12) | 1.0000 |
| Pharyngitis | 0 (0.00) | 1 (1.12) | 1.0000 |
| Nasopharyngitis | 1 (1.12) | 0 (0.00) | 1.0000 |
| Investigations | 1 (1.12) | 1 (1.12) | 1.0000 |
| Liver function test abnormal | 0 (0.00) | 1 (1.12) | 1.0000 |
| Creatine phosphokinase increased | 1 (1.12) | 0 (0.00) | 1.0000 |
| Lactate dehydrogenase increased | 1 (1.12) | 0 (0.00) | 1.0000 |
| Injury and procedural complications | 0 (0.00) | 1 (1.12) | 1.0000 |
| Ligament sprain | 0 (0.00) | 1 (1.12) | 1.0000 |
| Metabolism and nutrition disorders | 0 (0.00) | 1 (1.12) | 1.0000 |
| Hypertriglyceridemia | 0 (0.00) | 1 (1.12) | 1.0000 |
| Musculoskeletal disorders | 0 (0.00) | 1 (1.12) | 1.0000 |
| Myalgia | 0 (0.00) | 1 (1.12) | 1.0000 |
| Reproductive system disorders | 1 (1.12) | 0 (0.00) | 1.0000 |
| Menopausal disorder | 1 (1.12) | 0 (0.00) | 1.0000 |
| Total | 5 (5.62) | 10 (11.24) | 0.1773 |
Data are presented as the n (%).
AML, amlodipine; CC, candesartan cilexetil.